Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials

Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials

Abstract Background Nonalcoholic steatohepatitis (NASH), now metabolic-associated steatohepatitis (MASH), is a progressive liver disease with limited treatment options. This review evaluated the efficacy and safety of resmetirom, a selective thyroid hormone receptor beta (THR-β) agonist, for MASH tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Ikponmwosa Jude Ogieuhi, Gbolahan Olatunji, Emmanuel Kokori, Olanrewaju Adeniran, Wuraola Awosan, Ifeoma Kwentoh, Owolabi Samuel, Oluwafemi Isaiah Ajimotokan, Okam Onyinyechi Victoria, Abdulrahmon Moradeyo, Deborah Aboyeji, Tejiri Napoleon, Chidinma Udojike, Chimezirim Ezeano, Yewande Abigail Adebayo, Reem Gamaleldin Hassan Mohamed, Nicholas Aderinto
Format: Article
Language:English
Published: SpringerOpen 2025-06-01
Series:The Egyptian Journal of Internal Medicine
Subjects:
Metabolic associated steatohepatitis (MASH)
Resmetirom
Thyroid hormone receptor beta (THR-β)
Liver fibrosis
Hepatic fat content
Online Access:https://doi.org/10.1186/s43162-025-00468-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s43162-025-00468-z

Similar Items